Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Patients With Recurrent Platinum-resistant Ovarian Cancer: Phase II Study

NCT05467670 is registered in ClinicalTrials.gov with Alexander B Olawaiye, MD as lead sponsor.

NCT NCT05467670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05467670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Patients With Recurrent Platinum-resistant Ovarian Cancer: Phase II Study
Lead sponsor
Alexander B Olawaiye, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 30, 2023
Completion date
April 13, 2029
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer